Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

Trial Profile

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 25 May 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2018 Status changed from not yet recruiting to recruiting.
    • 07 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Apr 2018.
    • 04 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top